Navigation Links
Study: Modafinil is effective in treating excessive sleepiness
Date:10/15/2007

WESTCHESTER, Ill. A study published in the October 15 issue of the Journal of Clinical Sleep Medicine (JCSM) finds that modafinil is well-tolerated in the treatment of excessive sleepiness associated with disorders of sleep and wakefulness such as shift work sleep disorder, obstructive sleep apnea (OSA) and narcolepsy, and does not affect cardiovascular or sleep parameters.

The study, authored by Thomas Roth, PhD, of the Henry Ford Sleep Center in Detroit, Mich., focused on 1,529 outpatients who received modafinil 200, 300 or 400 mg, or a placebo once per day for up to 12 weeks. A total of 934 patients received modafinil, and 567 received a placebo. The subjects were assessed for adverse events and effects of modafinil on blood pressure/heart rate, electrocardiogram intervals, polysomnography, and clinical laboratory parameters.

According to the results, modafinil was well tolerated versus a placebo, with headache, nausea and infection the most common adverse side effect. The overall incidence of side effects was similar among the three modafinil dosage groups. Adverse events occurring more frequently in the modafinil group than in controls included headache, nausea, dry mouth, anorexia, nervousness, insomnia, anxiety, hypertension and pharyngitis. In patients taking modafinil, 19 serious adverse events occurred, while in the placebo group, there were 10 serious adverse events.

In modafinil-treated patients clinically significant increases in diastolic or systolic blood pressure were infrequent. In the narcolepsy studies one patient in the modafinil group and one in the placebo group had a clinically significant increase in heart rate.

New clinically meaningful electrocardiogram abnormalities were rare with the modafinil and placebo group.

Modafinil did not affect sleep architecture in any patient population according to polysomnography.

Clinically significant abnormalities in mean laboratory parameters were observed in less than one percent of patients in modafinil-treated patients at the final visit.

Modafinil is well tolerated. Furthermore, it appears from these prospective research studies that daily modafinil administration confers a low risk of adverse events or severe adverse events. These results make for a positive risk-benefit ratio for using modafinil to treat excessive sleepiness in patients with shift work sleep disorder, OSA and narcolepsy, said Dr. Roth.

The American Academy of Sleep Medicine (AASM) recommends that people who suspect that they might have a sleep disorder see a primary care physician or a sleep medicine specialist for proper diagnosis and to discuss treatment options before treatment with medications is undertaken.

While modern hypnotics are considered safe, individuals should be aware that, like all medications, side effects may occur in patients.

Sleep medications are effective and safe treatments when used properly and judiciously by a patient who is under the supervision of a sleep medicine or primary care physician.


'/>"/>

Contact: Jim Arcuri
jarcuri@aasmnet.org
708-492-0930
American Academy of Sleep Medicine
Source:Eurekalert

Related medicine news :

1. Counter study: cholesterol drugs no good in preventing colon cancer
2. A strategic study: Soy diet makes heart disease to worsen in male mice
3. Bird Flu Pandemic Study: Clerical & Support Staff May Stay At Home
4. Study: Older Pancreatic Cancer Surgery Survivors Live Long
5. New Study: Pine Bark Significantly Reduces Endometriosis
6. New Way to "See" Genes, Evaluate Effectiveness of Gene Therapies Discovered
7. Inhaled Steroids Safe & Effective for Children with Asthma
8. Morning after pill effective up to five days after having unprotected sex
9. Distraction therapy found very effective in postoperative patients
10. ZD1839 Proves Effective - A Breakthrough in fighting Lung Cancer
11. TELITHROMYCIN - the proven effective new drug for cap
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... New York, NY (PRWEB) , ... April 28, ... ... Shiel Medical Laboratory to expanded distribution of the GlycoMark test throughout the Northeast ... indicates recent hyperglycemia in patients with diabetes. The GlycoMark test provides a clinically ...
(Date:4/28/2017)... ... April 28, 2017 , ... Ushio America proudly ... offer an instant energy-saving solution for F32T8 fluorescent lamps on most instant-start and ... These 50,000 hour rated lamps utilize the existing electronic ballast, saving labor and ...
(Date:4/28/2017)... ... April 28, 2017 , ... Datta Endoscopic Back Surgery and ... revolutionary endoscopic practice under Dr. Datta. Patel is a Board Certified Anesthesiologist, with ... revolutionary eDiscSculpt Technique created and used by Datta Endoscopic is unlike traditional back ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... The Texas ... in recently to the labor and delivery team at Women’s Hospital at Renaissance in ... who give birth at the hospital and decide to donate. , “Women’s Hospital ...
(Date:4/28/2017)... , ... April 28, 2017 , ... ... hERG liability could substantially improve drug safety and minimize the cost of development. ... validating ion channel inhibition using cell lines and for cardiac toxicity using induced ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... April 20, 2017   ZappRx, Inc ., a digital ... prescribing process, today announced it closed $25 million in Series ... capital firm based in Seattle that ... Partners . The Series B round included participation from ... 2014, and GV (formerly Google Ventures). As part ...
(Date:4/20/2017)... -- Eyevensys, a private biotechnology company developing ... technology that enables the safe, local, sustained production of ... range of ophthalmic diseases, announces it has received approval ... (MHRA) to advance its technology into clinical development. ... The EyeCET platform ...
(Date:4/19/2017)... - CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (the "Company"), announces that ... Conference 2017 at the Sheraton Hotel in Toronto, Ontario ... of the Company is scheduled to present on Tuesday, May 2 ... the Chairman of the Board, Tony Holler will also ... For more ...
Breaking Medicine Technology: